The COVID-19 pandemic challenged the way healthcare and the pharmaceutical industries delivered care to patients. Traditional methods for conducting clinical trials were disrupted in ways never seen before. This disruption forced both regulators and the industry to think progressively about how to enable and execute new or non-traditional methods for delivering care to patients. Innovative thinking and progressive regulatory policy allowed for the implementation of continuity solutions to accommodate the ongoing conduct of clinical trials while maintaining subject safety and data integrity.
The implementation of modern* solutions to ensure clinical trial continuity has impacted all stakeholders (e.g., sponsors, investigators, patients) involved in clinical research. As a result, there is a rich opportunity to understand the numerous lessons learned including both challenges and successes. These learnings can be used to inform future ways of working for industry as well as future policy by regulators. The Modernizing Clinical Trial Conduct (MCTC) Initiative is using data and experience to develop practical guidance and solutions that enable additional patient-centric options alongside on-site trial operations, where appropriate. The initiative will also look to engage other major stakeholders including regulators, patients, sites, and industry groups to further enable the modernization of clinical trial conduct. To support TransCelerate’s strategic priority to improve patient experience, a team within TransCelerate’s Modernizing Clinical Trial Conduct (MCTC) Initiative was tasked with exploring what a more patient-centric clinical trial could look like in 2031 and identifying potential areas where TransCelerate could play a role to enable this vision.
*Modern solutions or methodologies, for the purposes of this initiative, refers to employing technology solutions or services that enable additional patient-centric options alongside on-site trial operations, where appropriate.
• Acceleration of patient-centric approaches to clinical development
• Greater understanding of innovative clinical trial methodologies that support more effective patient engagement, when compared to traditional methods
• Potential to create efficiencies from accelerating health authority acceptance of innovative clinical development methods
Clinical Trials 2031 and Beyond: Report that utilizes a scenario planning exercise to explore the potential drivers influencing the future of clinical trials. Building on input from diverse thought leaders in the healthcare ecosystem, it further organizes the identified drivers into a matrix, which can be utilized to explore how combinations of the drivers might impact clinical trials in the future. To aid the thought process, the MCTC team has identified four potential future scenarios of clinical trials and outlined the characteristics of each scenario.
Participant Data Return Resource Pack: A document that provides access to a consolidated set of resources from within the clinical research ecosystem that can assist with returning individual data globally.
Maturity Survey Results: Blinded and aggregated findings from voluntary survey to understand collective experience of TransCelerate members deploying eight solutions of focus. The eight solutions in scope included: Direct-to-Patient Shipping, Telemedicine, Home Health Visits, Remote Site Monitoring, eConsent, Digital Data Collection Tools, Electronic Health Record (eHR) to Electronic Data Capture (EDC), and Local Community-Based Facilities.
Operational Complexity Assessment Tool: The Operational Complexity Assessment Tool (O-CAT) is an interactive tool that assesses the complexity or lack of complexity of implementing selected modern solutions in a clinical trial, based on several trial aspects that could potentially impact the circumstances of implementation. The O-CAT tool can help companies identify potential areas of focus during implementation planning and develop mitigation strategies to help lessen or avoid complex circumstances.
Process Frameworks: The Process Frameworks outline various considerations, from trial planning to study closeout, that sponsors may wish to think about when implementing selected solutions.
Beyond COVID-19: A catalyst paper formally assessing some of the lessons learned from continuity solutions implemented during the COVID-19 pandemic to identify interventions that the industry may want to further consider.